The financials
Ligand Pharmaceuticals Incorporated by the numbers
Ligand Pharmaceuticals Incorporated (LGND) reported revenue of $64M in Q2 2026 (quarter ended June 30, 2026), up 34% from the same quarter a year earlier. That came with net income of $49M (76% of revenue). For the full year FY2025, revenue was $268M (+60% year on year) and net income $124M. Its largest product in 2026-Q1 was Financial Royalty Assets at $10M, 20% of the disclosed total, just ahead of Material Sales Captisol at 17%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $64M | $48M | +34% |
| Operating income | $8.6M | $8.4M | +1.7% |
| Net income | $49M | $4.8M | +901% |
| Diluted EPS | $2.22 | $0.24 | +825% |
| Product | Revenue | Share |
|---|---|---|
| Financial Royalty Assets | $10M | 20% |
| Material Sales Captisol | $8.7M | 17% |
| Kyprolis | $6.7M | 13% |
| QARZIBA | $6.3M | 12% |
| Royalty Intangible Other | $3.8M | 7.4% |
| Rylaze | $3.2M | 6.4% |
| Financial Ohtuvayre Inventors | $3.0M | 6.0% |
| Intangible Ohtuvayre | $3.0M | 5.9% |
| Capvaxive | $2.0M | 3.9% |
| Vaxneuvance | $1.6M | 3.2% |
| Teriparatide Injection | $1.3M | 2.6% |
| Financial Royalty Other | $681K | 1.3% |
| Contract Revenue And Income | $110K | 0.2% |
| Contract Revenue And Other Income | $110K | 0.2% |
| Contract | $110K | 0.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $50.6M (-70%)
Capvaxive grew +122% year on yearContract -97% year on year
Segment Latestquarter on quarteryear on year
- Financial Royalty Assets$10.0M$10.0MQoQ +56%year on year +70%+56%+70%
- Material Sales Captisol$8.7M$8.7MQoQ -19%year on year -36%-19%-36%
- Kyprolis$6.7M$6.7MQoQ -42%year on year +43%-42%+43%
- QARZIBA$6.3M$6.3MQoQ +5.4%year on year +16%+5.4%+16%
- Royalty Intangible Other$3.8M$3.8MQoQ +10.0%year on year +2.5%+10.0%+2.5%
- Rylaze$3.2M$3.2MQoQ -9.4%year on year +3.3%-9.4%+3.3%
- Financial Ohtuvayre Inventors$3.0M$3.0MQoQ -year on year ---
- Intangible Ohtuvayre$3.0M$3.0MQoQ -year on year +112%-+112%
- Capvaxive$2.0M$2.0MQoQ -39%year on year +122%-39%+122%
- Vaxneuvance$1.6M$1.6MQoQ -21%year on year +25%-21%+25%
- Teriparatide Injection$1.3M$1.3MQoQ -50%year on year +11%-50%+11%
- Financial Royalty Other$681.0K$681.0KQoQ +52%year on year +48%+52%+48%
- Contract Revenue And Income$110.0K$110.0KQoQ -year on year -97%--97%
- Contract Revenue And Other Income$110.0K$110.0KQoQ -100%year on year -97%-100%-97%
- Contract$110.0K$110.0KQoQ -16%year on year -97%-16%-97%
- Contract And Revenue Income Other--QoQ -year on year ---
- Evomela--QoQ -year on year ---
- Income From Divestiture Transactions--QoQ -year on year ---
- Milestone And Other--QoQ -year on year ---
- Ohtuvayre--QoQ -year on year ---